We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Potential benefit of dose‐escalated stereotactic body radiation therapy using CyberKnife for early‐stage primary lung cancer.
- Authors
Watanabe, Shou; Yamazaki, Hideya; Kimoto, Takuya; Shiomi, Hiroya; Yamada, Kei; Suzuki, Gen
- Abstract
Introduction: The study aimed to evaluate the efficacy and safety of dose‐escalated stereotactic body radiotherapy (SBRT) for primary lung cancer. Methods: Patients with peripherally located T1‐2N0M0 primary lung cancer who underwent SBRT from April 2013 to December 2019 were included. Group A received 60 Gy in five fractions with CyberKnife prescribed at 99% gross tumor volume. Group B received 48 Gy in four fractions by a gantry‐mounted linear accelerator, with isocenter prescription. Cumulative incidence of local failure (LF), progression free survival (PFS), overall survival (OS), and toxicity were retrospectively compared. Results: Groups A and B comprised 39 and 36 patients, respectively. Group A had more patients without histological confirmation (p <.001) and showed lower V20 of bilateral lungs (p =.025). The median follow‐up duration of Group A and B was 22.0 and 21.5 months, respectively, and the 2‐year cumulative incidence of LF, PFS, and OS were.0% versus 11.6% (p =.065), 66.2% versus 62.7% (p =.694), 84.1% versus 81.1% (p =.827), respectively. There was no difference in Grade ≥ 2 toxicity rate between Groups A and B (7.7% vs. 11.1%; p =.704). Conclusion: Dose‐escalated SBRT using CyberKnife showed reduced lung dose and potential benefits for improved local control with comparable toxicity.
- Subjects
STEREOTACTIC radiotherapy; LUNG cancer; PROGRESSION-free survival; NON-small-cell lung carcinoma; PULMONARY nodules
- Publication
Asia Pacific Journal of Clinical Oncology, 2023, Vol 19, Issue 3, p320
- ISSN
1743-7555
- Publication type
Article
- DOI
10.1111/ajco.13842